Aug 14, 2018
Sigilon Therapeutics Announces Leadership Transition and Appoints Rare Disease Pioneer Rogerio Vivaldi, M.D., as Chief Executive Officer
May 02, 2018
Sigilon Therapeutics to Present at the 2nd International Pancreas and Islet Transplant Association-JDRF-Harvard Stem Cell Institute Key Opinion Leaders Meeting on Stem Cell Derived Beta Cells
Apr 06, 2018
Sigilon Therapeutics to Present at the GTCbio 15th Stem Cell Summit
Apr 04, 2018
Lilly and Sigilon Therapeutics Announce Strategic Collaboration to Develop Encapsulated Cell Therapies for the Treatment of Type 1 Diabetes
Mar 09, 2018
Sigilon Therapeutics to Present at Cowen & Company 38th Annual Health Care Conference
Mar 08, 2018
Sigilon Therapeutics Receives Advanced Therapy Medicinal Product Designation for Afibromer(TM)-Based Living Therapeutic Program
Feb 23, 2018
Sigilon Therapeutics to Present at Upcoming Scientific and Investor Conferences
Feb 08, 2018
Sigilon Therapeutics to Present at Upcoming Conferences
Jan 04, 2018
Sigilon Therapeutics Appoints David E. Moller, M.D., as Chief Scientific Officer
Jan 02, 2018
Sigilon Therapeutics to Present at Upcoming January Conferences
Nov 10, 2017
Sigilon Therapeutics to Present at the 2017 Biotech and Money InvEUR$tival Showcase Conference in London
Nov 01, 2017
Sigilon Therapeutics Appoints Eric Shaff to Board of Directors
Oct 16, 2017
Sigilon Therapeutics Introduces Scientific Advisory Board for Guiding Development of Afibromer(TM) Living Therapeutics
Oct 12, 2017
Sigilon Therapeutics to Present at the 16th Annual BIO Investor Forum in San Francisco
Sep 29, 2017
Sigilon Therapeutics to Present at the 2017 Cell & Gene Meeting on the Mesa
Sep 07, 2017
Sigilon Therapeutics to Present at Upcoming September Conferences
Jun 21, 2017
Flagship Pioneering Launches Sigilon Therapeutics to Advance Afibromer(TM) Encapsulated Cell Therapies